A big thank you to our wonderful growing #radonc community on Twitter who made our first monthly journal club of 2020 a success! Click here to see a summary of out last month’s “Role of Local Ablative Therapy in Oligoprogression”.
We will be discussing an article on post-radiation late effects this month for #radonc journal club:
The article provides a review assessing the current status of prospective reporting of late morbidity after curative radiation therapy in large clinical studies. With an increasing emphasis on cancer survivorship driven by improved survival in cancer patients, there is a need to understand the dynamic complex nature of therapy-related late morbidity and differentiate fact from myth. The significance of comprehensive morbidity reporting is evidenced by its crucial role in constant assessment of dose/volume constraints for normal tissue, need for establishing new radiation therapy techniques to decrease toxicity, and enhancing the value of shared decision making. The authors selected papers published between 12/2015 through 11/2017, looking at prospectively assessed late morbidity associated with endpoints relevant for radiation therapy. Several recommendations were made by the authors to assist in comprehensive morbidity reporting in a standardized way to assist in future clinical care.
Please join us in welcoming author Dr. Anders Schwartz Vittrup (@VittrupAnders), a radiation oncologist at Aarhus University Hospital in Denmark. Dr. Jane Maher (@MaherJane), an oncologist and former Chief Medical Officer of Macmillan Cancer Support in the United Kingdom, as a discussant. We will discuss the significance of comprehensive reporting of therapy-related late morbidity.
Our chat will begin 8AM Central Standard Time on Saturday February 15th and carry through into Sunday. We will have a “live hour” on 2PM Central Standard Time on Sunday February 16th. This International Journal of Radiation Oncology*Biology*Physics article will be open access for the journal club from Monday, February 10th, 2020 through Monday February 17th 2020.
T1. Why is therapy-related comprehensive morbidity reporting important?
T2. Comment on the importance of reporting mild toxicity. Implications on quality of life (QOL)? Compare the challenges associated with reporting mild-moderate toxicity vs serious side effects. Is mild toxicity more likely to be captured by patient reported outcomes (PROs) vs physician reported?
T3. What is the significance of PROs in complementing physician-assessed morbidity? Downfall of using PROs only?
T4. There is a need for a standardized severity grading scale and PRO questionnaire for at least a specific cancer type. What is the likelihood of this dream becoming a reality?
Any suggestions? Leave a comment or tweet us at @Rad_Nation. We look forward to having you join us!